Previously, Kossel Medtech (Suzhou) Co., Ltd. (hereinafter referred to as “Kossel Medtech”) completed the strategic acquisition of the peripheral vascular intervention business of Shanghai Biotriton Medical Technology Co., Ltd (hereinafter referred to as “Biotriton Medical”), further strengthening Kossel Medtech’s comprehensive one-stop diagnosis and treatment portfolio in the peripheral intervention field.
Recently, Biotriton Medical’s independently developed K-VisionMax™ Peripheral IVUS System, including the Peripheral Intravascular Ultrasound Diagnostic Catheter (Registration No.: GXZZ 20263061165) and the Intravascular Ultrasound Diagnostic System (Registration No.: GXZZ 20263061218), has successfully received market approval from the National Medical Products Administration (NMPA).
K-VisionMax™ Peripheral IVUS System
Four Key Advantages
30 MHz High-Definition Imaging
Equipped with a 30 MHz mechanically rotating transducer, delivering clearer images and richer anatomical details.
40 mm Ultra-Wide Imaging Range
Featuring an extra-large 40 mm imaging diameter, enabling comprehensive visualization of both arteries and veins while meeting the demands of complex clinical cases.
0.018″ Rapid-Exchange Design
Compatible with standard 0.018″ guidewires and 6F introducer sheaths, allowing for easier operation and minimizing procedural trauma.
Comprehensive Clinical Application
Designed to support a full spectrum of peripheral vascular interventions, including the carotid arteries, lower-extremity arteries and veins, iliac veins, and other peripheral vascular applications.
As an important milestone in China’s peripheral vascular intervention sector, the K-VisionMax™ Peripheral IVUS System integrates high-definition imaging, procedural convenience, and broad clinical applicability into a single platform. It provides clinicians with a cost-effective and precise intravascular imaging solution, ushering in a new era of precision diagnosis and treatment in peripheral vascular intervention and benefiting more patients.
Recently, MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System, the flagship product of Mixin Medtech, a subsidiary of Kossel Group, has been successfully approved for market launch by the National Medical Products Administration (NMPA) (Registration Certificate No.: GXZZ 20263130833).
MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System was developed following Kossel Group’s complete acquisition of Micell Tech. By integrating innovative technology with China’s Intelligent Manufacturing, it provides a new clinical option for Percutaneous Coronary Intervention (PCI) that features both rapid healing and long-lasting efficacy.
Dual-Excellence Design: Balancing Healing Efficiency and Long-Term Protection
Rapid Healing: Ultra-Thin Stent for Fast Endothelialization
The domestic MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System is built on a 64 μm ultra-thin cobalt-chromium alloy platform, thereby minimizing vessel injury. Its absorbable drug coating eliminates drug burst release and does not inhibit early endothelialization, enabling faster healing.
Long-Lasting Efficacy: Controlled Sustained Release for Full Coverage
Crystalline sirolimus achieves an extra-long 9-month sustained release, persistently inhibiting intimal hyperplasia and vascular inflammation triggered during polymer elution and absorption.
As the core product of Mixin Medtech, the market approval of MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System further completes the company’s product portfolio in the coronary intervention field. Moving forward, the company will continue to be clinical-needs oriented, accelerate the commercialization of more high-quality medical device achievements, inject strong impetus into vascular disease diagnosis and treatment, and support the construction of the **Healthy China** initiative.
January 20, 2026 – The strategic cooperation signing ceremony between Kossel Medtech (Suzhou) Co., Ltd (“Kossel”) and Medtronic (Shanghai) Management Co., Ltd. (“Medtronic”) was successfully held. This collaboration marks the establishment of a deep strategic partnership. Centered on Kossel’s core product, the Seledora® Coronary Scoring Balloon Catheter, the two sides will work together to promote its clinical application and benefit more patients with coronary artery disease.
Senior leaders from both companies attended the ceremony, including Mr. Gu Yushao, Sr. Vice President, President of Greater China; Mr. Hu Qing, Founder and CEO of Kossel; Mr. Tao Jia, VP China CRDN; Ms. Pan Xingzhen, Executive President of Kossel; and Mr. Zhou Quan, VP of Strategy & BI and Partnerships & Digital Innovation, etc, and witness this grand event of industry together.
Strategic Synergy: Connecting Local Innovation power with Global Resources
This partnership represents a deep integration of local innovative strength and global medical technology leadership, bringing new momentum to coronary intervention.
Kossel, as a local innovator in cardiovascular intervention, focuses on developing high-end medical devices based on clinical needs. Its self-developed Seledora® Coronary Scoring Balloon offers a precise solution for complex lesions like moderate-to-severe calcification. Medtronic, a global leader, brings its extensive nationwide network, professional clinical promotion system, and deep industry resources in China to support the widespread adoption of this innovative product.
Both parties believe this collaboration is a key step for the commercialization of Kossel’s product and an important move for Medtronic’s localization strategy. By combining strengths, we aim to accelerate the introduction of valuable clinical solutions and help raise treatment standards.
Co-creating the Future: Building an Innovation Ecosystem for Healthy China
This collaboration is strategically significant for both. Kossel will leverage Medtronic’s comprehensive system to rapidly increase the accessibility of Seledora® scoring balloons. Medtronic, by partnering with the locally-engaged innovator Kossel, aims to better integrate global experience with Chinese practice, respond faster to clinical needs, improve solutions for complex patients, and promote standardized, sustainable development in coronary therapy.
Leadership Perspectives:
Mr. Gu Yushao: “Chinese healthcare is evolving towards quality, stability, and sustainability. Medtronic is committed to fostering local innovation. Partnering with Kossel is a win-win to create a pathway tailored to China’s needs and deliver long-term clinical value.”
Mr. Hu Qing: “Addressing complex coronary cases drives our innovation. True innovation requires not just technology, but also standardized application and promotion, which needs a mature system’s support. Partnering with Medtronic, who shares our patient-centric and long-term vision, is a natural step to advance local innovation and release greater clinical value.”
Mr. Tao Jia: “The growing scale and complexity of cases require a new stage of precise, multi-device therapy. No single technology suffices. Partnering with Kossel allows us to combine global experience with local practice, improving solutions for complex patients and promoting standardized, sustainable development.”
Ms. Pan Xingzhen: “The Seledora® balloon catheter is built on a solid foundation of R&D, quality, and clinical support. This collaboration focuses not only on the product but also on aligning our working mechanisms. Kossel will continue to develop mature products, complementing Medtronic’s strengths to offer richer, more reliable solutions.”
Both parties will establish comprehensive collaboration mechanisms across product promotion, academic exchange, and clinical research. By integrating R&D innovation with commercial expertise, we aim to build a better coronary intervention ecosystem, advance cardiovascular disease treatment, and contribute to the “Healthy China” initiative.
How to address the issue that the angle between the inferior vena cava and the left iliac vein is large and there is a risk of tilting during the filter release？
From November 17th to 20th, MEDICA 2025, the world’s premier medical extravaganza, grandly took place in Düsseldorf, Germany.
Amid this feast of ideas gathering global cutting-edge technology and medical wisdom, we outlined the future blueprint of the healthcare industry through frontier technologies, innovative products, and in-depth dialogues.
Chinese Solutions on the International Stage
Bringing its latest technological achievements and industry insights, Kossel explored cutting-edge trends with global partners. A number of innovative achievements and solutions across three major product lines—Peripheral Vascular, Coronary, and Electrophysiology—made a stunning debut, demonstrating the innovative vitality of Chinese medical enterprises on the global stage.
During the exhibition, we conducted in-depth negotiations with agents and physician representatives from multiple countries in Europe, the Americas, Asia, and other regions. While discussing product features, we accurately aligned with registration requirements and clinical needs, laying a solid foundation for the deepening of future cooperation.
Europe is Kossel’s key strategic market. The company successfully obtained MDR CE certification in May this year, removing critical barriers for product entry into the European market. In the future, we will continue to launch more high-quality products, continuously enhance brand influence and market share, and support the company’s long-term development in Europe.
Every medical technology event marks the starting point of a new journey. We will embark on the next phase with the trust of global partners, persist in innovative R&D, advance the global market layout in parallel, focus deeply on the application needs in the pan-vascular intervention field, and provide more innovative and practical products and solutions for physicians and patients worldwide.
How to address the issue that the angle between the inferior vena cava and the left iliac vein is large and there is a risk of tilting during the filter release？
From October 23 to 24, 2025, the 2025 Complex Cardiovascular Therapeutics (CCT 2025) was grandly held in Kobe, Japan. As one of the most influential academic conferences on cardiovascular interventional therapy in Asia, it shares the latest advancements in PCI therapy, structural heart disease, and surgical treatment through live surgical demonstrations, special seminars, and academic reports. The conference attracts cardiovascular experts from around the world and has become an internationally recognized high-level academic exchange platform.
As one of the few Chinese manufacturers exhibiting at CCT, Kossel made a focused appearance with a range of star products and localized solutions, showcasing the company’s latest technologies and achievements to medical professionals.
Kossel’s exhibition team received doctors and agents from Japan and other Asian countries during the conference, and conducted in-depth exchanges on concepts, strategies, new devices, and clinical research.
Focused on the pan-vascular intervention field, Kossel has been committed to bringing original Chinese medical technologies and achievements to more doctors and patients. In 2021, Kossel’s PTCA balloon obtained certification in Japan. In addition, Japan serves as one of the clinical centers for Kossel’s coronary product, the MiStent® coronary drug-eluting stent, which has gained partial market recognition and laid a foundation for product promotion. More localized products and solutions will be developed and launched in the future.
Going forward, Kossel will continue to deepen innovative R&D in the pan-vascular intervention field, advance the layout of the Asian market simultaneously, and focus closely on application needs in the pan-vascular intervention sector. It aims to provide more innovative and practical products and solutions for doctors and patients in Asia and beyond.
Recently, Kossel Medtech (Suzhou) Co., Ltd. received approval from the National Medical Products Administration (NMPA) for its independently developed Peripheral Thrombectomy Catheter (Registration No. 20253031757).
This product, together with the previously approved Medical Electric Suction Pump (Registration No. 20252141564), Disposable Suction Connection Tube (Registration No. 20252141452), Negative Pressure Collection Device (Registration No. 20252109), and the separator currently under registration, forms the “K-Rhino” Peripheral Thrombectomy System, designed for aspiration of thrombi in peripheral arteries and veins.
While the industry remains within the “comfort zone” of 8–12F, we chose to push the boundary. 14F is not a gamble on size—it is an exploration for greater efficiency in peripheral thrombectomy.
Why are existing aspiration catheters sometimes insufficient?
When the thrombus burden is high, the lesion is located distally, or the thrombus is highly adherent, do you ever find that with 8–10F catheters:
Aspiration feels inadequate?
Residual thrombus remains despite repeated attempts?
Thrombectomy is incomplete, time-consuming, with significant blood loss?
Catheter-directed thrombolysis becomes necessary afterward, carrying bleeding risks?
The root cause: Insufficient aspiration efficiency.
How to break through?
Two core factors determine aspiration efficiency:
Thrombus Removal Force: The catheter’s ability to capture thrombus
Thrombus Transport Capacity: The catheter’s ability to deliver thrombus through its lumen
1. Catheter Diameter Determines Thrombus Removal Force
Mechanical principle:
When the thrombus completely occludes the catheter tip, a larger catheter diameter generates a greater removal force, resulting in stronger aspiration power.
2. Catheter Diameter Determines Thrombus Transport Capacity
Mechanical principle: Hagen–Poiseuille’s Law
Thrombus transport capacity is directly proportional to catheter radius—the larger the diameter, the greater the transport efficiency.
In summary: The closer the catheter diameter is to the vessel diameter (without exceeding it), the higher the aspiration efficiency.
This is the rationale behind the 14F large-lumen aspiration concept, leading to the K-Rhino 14F Aspiration Catheter.
Three Key Facts About the 14F Aspiration Catheter 1. Deliverability
Is 14F too large for the iliac-femoral vein?
For peripheral thrombectomy, the catheter size should match the vessel diameter.
Common access: popliteal vein
popliteal vein diameter(4.5–7 mm), femoral vein (5–8 mm), iliac vein (8–12 mm).
14F catheter outer diameter: 4.66 mm—well within the vessel range and safely deliverable. 2. Blood Loss
With 14F, aspiration efficiency improves, residual thrombus is reduced, and procedure time shortens. Blood loss remains within a normal range.
Technique tip: When transparent tubing shows a sudden increase in blood flow, stop aspiration, reposition the catheter tip to the thrombus, then resume. 3. Safety
A soft distal tip minimizes vascular injury.
In Vitro Study Objective: To analyze the correlation between catheter diameter, thrombus clearance rate, and blood loss.
Method: 8F, 10F, 12F, and 14F catheters were used to aspirate thrombi in a 7 cm iliac vein segment. Metrics: aspiration time, total blood loss, and catheter occlusion events.
Experimental Results
Experimental Conclusion
Compared with 8F, 10F, and 12F catheters, the 14F aspiration catheter demonstrated higher aspiration efficiency, lower total blood loss, and no catheter occlusion.
K-Rhino 14F Peripheral Thrombectomy Catheter
A new era of large-lumen aspiration begins.
Disclaimer: This article is an interpretation of a medical device product and aims to provide users with scientific and objective information. It does not constitute medical advice, diagnosis, or treatment recommendations. Clinical data and indications may evolve with ongoing research, and the company makes no guarantee of permanent validity. The cases, data, and study results cited herein are for knowledge sharing only and do not apply to all individuals. Outcomes may vary due to patient differences—please do not attempt imitation or self-diagnosis.
Recently, the three types of PTCA balloon catheters developed independently by Kossel – Selethru II (SC, NC26, Super NC) – have obtained the certificate from the KFDA.
Until now, the Selethru PTCA balloon catheter has been approved for sale in Asia, the Middle East, South America, and other regions. With its outstanding clinical performance, it has gained recognition.
In response to the different clinical needs in South Korea, Kossel responded promptly and upgraded the Selethru PTCA balloon catheter. We customized it and launched the Selethru II (SC, NC26, Super NC) PTCA balloon catheter. Among them, the Selethru II Super NC has a maximum burst pressure of up to 36 atm, which will bring a better surgical experience to local surgeons and also help the company further expand the Asian market and bring hope to more patients.
In the future, Kossel will continue to strive to promote high-quality medical devices from China to more countries around the world, benefiting more patients globally.
